British Biotech nears cancer drug deal
Tuesday 07 September 1999
A company source yesterday said a deal was "imminent". Shares in the company closed up 6.25p, or 20 per cent, at 37.25p yesterday following reports at the weekend that a licensing deal would be announced the company's annual meeting, scheduled for 23 September.
However, it now appears a deal is ready to be signed. Possible candidates for the partnership include US groups Merck, Pharmacia & Upjohn, and Eli Lilly.
The partnership agreement is expected to take the form of an upfront licence fee, with regular milestone payments tied to further trials.
The deal follows the publication last month of mixed results for Marimastat, a treatment for gastric cancer, in clinical trails. While the drug failed in its primary goal of prolonging overall survival significantly at a pre-determined end-point, the company claims it was successful if the data from nine patients, who violated the trial's protocol, were discounted.
The drug showed also significant effects in arresting the development of tumours, a secondary target of the study, prompting the company to approach regulators for possible marketing approval of the drug.
Even if Marimastat becomes a commercial product, it may not lead to a revival in the fortunes of British Biotech, whose shares crashed in 1997 after one its directors took issue publicly with its statements about drugs in development. The company's management has since been overhauled.
While there is no available treatment for gastric cancer after chemotherapy or operation, some observers doubt whether doctors would allocate resources to a treatment which adds perhaps only days to a patient's life.
- 1 Pope Francis issues top 10 tips for happiness
- 2 Disney heiress Abigail disowns her share of family profits in West Bank company
- 3 The secret report that helps Israel hide facts
- 4 Now diplomacy has failed, boycotting Israel might be the only way we can protect the people of Gaza
- 5 Israel's propaganda machine is finally starting to misfire
Russell Brand accuses Sean Hannity of terrorism after aggressive Israel-Gaza debate
Pope Francis issues top 10 tips for happiness
Justin Bieber posts Instagram photo of a crying Orlando Bloom after Ibiza fight 'over Miranda Kerr'
Disney heiress Abigail disowns her share of family profits in West Bank company
Air Algerie AH5017 crash: Jet fell 30,000 feet in three minutes ‘due to violent storm’
The secret report that helps Israel hide facts
Land for gas: Merkel and Putin discussed secret deal could end Ukraine crisis
Woman and two children killed by mob in riots over 'blasphemous' Facebook post in Pakistan
Richard Dawkins tweets: 'Date rape is bad, stranger rape is worse'
Putin is 'thuggish, dishonest and reckless', says British ambassador to US
Boozy, ignorant, intolerant, but very polite – Britain as others see us
- < Previous
- Next >
iJobs Money & Business
£28000 - £32000 per annum + benefits: Ashdown Group: Training Programme Manage...
£20000 - £24000 per annum: Harrington Starr: A leading provider of web based m...
£28000 - £32000 per annum: Ashdown Group: Secretary (Sales Team Support) - Mat...
Competitive (DOE): Guru Careers: We are looking for an Assistant Management Ac...